Baseline characteristics of ADRs to anticoagulants anticoagulant in Spain during the period 2010–2013
| 2010 N (%) | 2011 N (%) | 2012 N (%) | 2013 N (%) | Total N (%) | p Value | |
|---|---|---|---|---|---|---|
| Female | 5509 (52.89) | 6264 (52.41) | 7287 (52.86) | 7304 (52.58) | 26 364 (52.68) | 0.857 |
| Age, mean (SD) | 78.92 (9.6) | 79.24 (9.56) | 79.66 (9.48) | 79.81 (9.51) | 79.45 (9.54) | <0.0001 |
| Charlson comorbidity index, mean (SD) | 1.61 (1.07) | 1.64 (1.08) | 1.68 (1.09) | 1.74 (1.09) | 1.67 (1.09) | <0.0001 |
| Myocardial infarction | 547 (5.25) | 610 (5.1) | 649 (4.71) | 580 (4.18) | 2386 (4.77) | <0.0001 |
| Congestive heart failure | 3987 (38.28) | 4581 (38.33) | 5697 (41.33) | 5949 (42.83) | 20 214 (40.39) | <0.0001 |
| Peripheral vascular disease | 537 (5.16) | 659 (5.51) | 743 (5.39) | 810 (5.83) | 2749 (5.49) | 0.131 |
| Cerebrovascular disease | 1225 (11.76) | 1410 (11.8) | 1546 (11.22) | 1645 (11.84) | 5826 (11.64) | 0.332 |
| Dementia | 478 (4.59) | 560 (4.69) | 686 (4.98) | 666 (4.79) | 2390 (4.78) | 0.524 |
| Chronic pulmonary disease | 3070 (29.48) | 3562 (29.81) | 4181 (30.33) | 4319 (31.09) | 15 132 (30.24) | 0.032 |
| Connective tissue disease—rheumatic disease | 248 (2.38) | 256 (2.14) | 275 (1.99) | 329 (2.37) | 1108 (2.21) | 0.102 |
| Peptic ulcer disease | 188 (1.81) | 181 (1.51) | 216 (1.57) | 174 (1.25) | 759 (1.52) | 0.006 |
| Mild liver disease | 415 (3.98) | 444 (3.72) | 523 (3.79) | 567 (4.08) | 1949 (3.89) | 0.403 |
| Diabetes without chronic complication | 2650 (25.44) | 3104 (25.97) | 3512 (25.48) | 3623 (26.08) | 12 889 (25.76) | 0.541 |
| Diabetes with chronic complication | 290 (2.78) | 327 (2.74) | 423 (3.07) | 450 (3.24) | 1490 (2.98) | 0.059 |
| Hemiplegia or paraplegia | 111 (1.07) | 150 (1.26) | 187 (1.36) | 199 (1.43) | 647 (1.29) | 0.075 |
| Renal disease | 2194 (21.07) | 2672 (22.36) | 3290 (23.87) | 3552 (25.57) | 11 708 (23.4) | <0.0001 |
| Cancer | 487 (4.68) | 650 (5.44) | 727 (5.27) | 718 (5.17) | 2582 (5.16) | 0.064 |
| Moderate or severe liver disease | 94 (0.9) | 115 (0.96) | 140 (1.02) | 143 (1.03) | 492 (0.98) | 0.752 |
| Metastatic carcinoma | 260 (2.5) | 316 (2.64) | 333 (2.42) | 365 (2.63) | 1274 (2.55) | 0.597 |
| AIDS/HIV | 11 (0.11) | 14 (0.12) | 12 (0.09) | 17 (0.12) | 54 (0.11) | 0.819 |
| Atrial fibrillation | 6441 (61.84) | 7450 (62.34) | 8792 (63.78) | 8924 (64.24) | 31 607 (63.16) | <0.0001 |
| Thromboembolism | 281 (2.7) | 283 (2.37) | 325 (2.36) | 335 (2.41) | 1224 (2.45) | 0.308 |
| Hypertension | 4156 (39.9) | 4835 (40.46) | 5618 (40.75) | 5452 (39.25) | 20 061 (40.09) | 0.059 |
| Anaemia | 3147 (30.22) | 3513 (29.4) | 4180 (30.32) | 4107 (29.57) | 14 947 (29.87) | 0.279 |
| Surgery | 689 (6.62) | 748 (6.26) | 774 (5.61) | 818 (5.89) | 3029 (6.05) | 0.007 |
| Red cell transfusion | 2063 (19.81) | 2339 (19.57) | 2678 (19.43) | 2360 (16.99) | 9440 (18.86) | <0.0001 |
| In-hospital mortality | 1042 (10) | 1205 (10.08) | 1491 (10.82) | 1424 (10.25) | 5162 (10.32) | 0.134 |
| LOSH, median (IQR) | 8 (5–13) | 7 (4–13) | 7 (4–12) | 7 (4–12) | 8 (4–13) | <0.0001 |
ADR, adverse drug reaction.